Focus on innovation and opportunity for companies and investors Key conference for life science and investing in the region with more than 200 international attendees Montreal, September 19, …
News
Acer Therapeutics and Opexa Therapeutics Sign Merger Agreement
Merger to create a pre-NDA-stage, NASDAQ-listed, pharmaceutical company focused on the development and commercialization of therapies for serious rare diseases with critical unmet medical …
Proteon Therapeutics Announces $22.0 Million Private Placement
Provides Sufficient Cash into Q4 2019 WALTHAM, Mass., June 22, 2017 (GLOBE NEWSWIRE) -- Proteon Therapeutics Inc. (Nasdaq:PRTO), a company developing novel, first-in-class therapeutics to address the …
CENTOGENE raises a EUR 25 million Series A financing to fuel innovation and to accelerate growth into personalized medicine
International consortium of investors led by TVM Capital Life Science together with DPE Deutsche Private Equity, Careventures and CIC Capital CENTOGENE will continuously expand its R&D …
Proteon Therapeutics Receives FDA Breakthrough Therapy Designation for Vonapanitase
WALTHAM, Mass., May 10, 2017 (GLOBE NEWSWIRE) -- Proteon Therapeutics, Inc. (Nasdaq:PRTO), a company developing novel, first-in-class therapeutics to address the medical needs of patients with kidney …
Attraktiv für Investoren! Individualisierte Medizin ist schon lange grundlegend für die erfolgreiche Behandlung von Patienten
Eine große Zahl von VC Investitionen im Life Science Bereich und deren Innovation sind implizit Investitionen in personalisierte Medizin oder Precision Medicine. Das können Beteiligungen an einer …